This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Vitamin D to Prevent Autism in Newborn Siblings

This study has been completed.
Information provided by (Responsible Party):
Gene Stubbs, Oregon Health and Science University Identifier:
First received: June 2, 2011
Last updated: May 5, 2016
Last verified: May 2016
The purpose of this study is to determine whether by administering vitamin D to mothers who already have at least one child with autism and who are pregnant, that the vitamin D will prevent the recurrence of autism in the newborn sibling.

Condition Intervention Phase
Autistic Disorder Drug: Vitamin D3 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Study of Vitamin D to Prevent Autism in Newborn Siblings

Resource links provided by NLM:

Further study details as provided by Gene Stubbs, Oregon Health and Science University:

Primary Outcome Measures:
  • Number of Children Who Developed Autism [ Time Frame: Child assessed at 3 years of age ]
    The child will be screened by an Modified Checklist for Autism in Toddlers (MCHAT) interview at 18 months of age, and by a questionnaire, the Pervasive Developmental Disorder Behavioral Inventory (PDDBI) at 3 years of age to determine whether the child has developed autism or not.

Secondary Outcome Measures:
  • Number of Mothers Who Developed Side Effects From Vitamin D [ Time Frame: During pregnancy and the 3 years of the child's development ]
    Mother will be followed by blood and urine screening for hypercalcemia and hypercalciuria which is the primary side effects of too much vitamin D.

Enrollment: 20
Study Start Date: February 2008
Study Completion Date: February 2016
Primary Completion Date: February 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Intervention during pregnancy
5000 IU Vitamin D3 to be given to the mother during pregnancy. 7000 IU Vitamin D3 to be given during breast feeding if breast feeding. If not breastfeeding, infant to be given 400 IU Vitamin D3 during first year of age, then increased to 1000 IU D3 until completion of research trial.
Drug: Vitamin D3
5000 IU D3 capsule oral/day for entire pregnancy. 7000 IU D3/day during breastfeeding. If not breast feeding, baby gets 400 IU D3/day. Baby increased to 1000 IU D3/day at one year of age.
Other Name: Cholecalciferol

Detailed Description:
The incidence of autism is increasing. Also, women of childbearing age are increasingly found to be insufficient/deficient in vitamin D. Vitamin D is a neurohormone which is important for development of the child, especially of the child's brain. The primary source of vitamin D is from the sun through one's skin. People have been avoiding the sun because of skin cancer, because of increasing Television watching, computer viewing and wearing clothes that cover most of the body. This approach will study whether making the pregnant mother, whose child is at risk for autism because of a previous child with autism, replete with vitamin D will prevent that recurrence of autism in the newborn sibling.

Ages Eligible for Study:   20 Years to 44 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Pregnant mothers who have had at least one child with autism spectrum disorder

Exclusion Criteria:

  • Child with autism must not be from a syndrome such as Fragile X syndrome, Retts Syndrome
  • Mother must be before the third trimester
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01366885

United States, Oregon
Evergreen Center
Oregon City, Oregon, United States, 97045
Sponsors and Collaborators
Oregon Health and Science University
Principal Investigator: Ervin G. Stubbs, M.D. Oregon Health and Science University
  More Information

Responsible Party: Gene Stubbs, Associate Professor Emeritus of Psychiatry and Pediatrics, Oregon Health and Science University Identifier: NCT01366885     History of Changes
Other Study ID Numbers: OHSU-AS-11-1-11
Study First Received: June 2, 2011
Results First Received: April 2, 2016
Last Updated: May 5, 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Please see publication in Medical Hypotheses-88(2016) 74-78-entitled: Autism: Will vitamin D Supplementation during pregnancy and early childhood reduce the recurrence rate of autism in newborn siblings? G. Stubbs et al.

Keywords provided by Gene Stubbs, Oregon Health and Science University:
Newborn siblings

Additional relevant MeSH terms:
Autistic Disorder
Child Development Disorders, Pervasive
Neurodevelopmental Disorders
Mental Disorders
Vitamin D
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents processed this record on September 20, 2017